“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality

By afschroeder • June 25, 2026

Sedrak MS, Ramalingam SS, Sparano JA. "Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality. Cancer. 2026 Jul 1;132(13):e70499. doi: 10.1002/cncr.70499. PMID: 42340000; PMCID: PMC13292070.

Tags: academic oncology, clinical investigator, Hematology/Oncology, Professional development, protected time, Publications

Related Posts

Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis

Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic[...]

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Srour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB,[...]

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW,[...]